ArticleBiochemical genetics2026
Cyclosporine A Modulates Neuroinflammation-Related Gene Expression Associated with Alzheimer's Disease in SH-SY5Y Neuronal Cell Line: Is Cyclosporine A Beneficial/Detrimental?
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Numerous investigations indicate that cyclosporine A (CsA) significantly influences the prevention or progression of Alzheimer's disease (AD) through various mechanisms. The precise pathways by which CsA, an inhibitor of calcineurin (CN) and peptidyl-prolyl isomerase A (PPIA), operates remain incompletely elucidated. In this study, we explored the effects of CsA, a widely utilized immunosuppressive agent, on the gene expression of various factors related to inflammation, cell adhesion, intercellular communication, and apoptosis in SH-SY5Y cells. We employed the semi-quantitative real-time PCR (RT-qPCR) method for gene expression analysis to assess these effects. Furthermore, network pharmacology was utilized to identify the potential targets of CsA and to further analyze. Our results demonstrated that CsA enhances the mRNA levels of most factors examined, including IL1B, S100A9, CD147, TREM2, LRP1, MAPK1, MAPK14, GSK3B, Dynamin 1, Dynamin 3, NLRP3, NLRP1, CASPASE 3, CASPASE 1, AIFM1, and STAT3. At the same time, it suppresses the mRNA levels of PPIA, TLR2, TLR4, PYCARD, RAGE, and BCL2. The network pharmacology analysis revealed seven target genes overlapping our experimental findings (PPIA, S100A9, TLR4, STAT3, MAPK1, MAPK14, and BAX). Our results suggest that CsA modulates gene expression in SH-SY5Y cells, with the potential for either beneficial/ harmful effects on cellular function, depending on the specific roles of the assessed genes.
Indexed as
Identifiers
40750957What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.